Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
VeraLight developed the first noninvasive, bloodless diabetes screening system using proprietary optical technology to detect biomarkers in the skin. Clinical trials showed its SCOUT DS device outperformed conventional blood-based tests for early detection of prediabetes and type 2 diabetes. The product received CE Mark and Health Canada approval but was not FDA approved as of last reports. The company targeted point-of-care settings such as pharmacies, clinics, and employer health programs. No recent clinical results are available post-market introduction.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on VeraLight.